Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 10/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 10/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | CPA2 | P48052 | 1/20 | 0.42 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433203 | 0.89 | KLKB1 (0.48) | ERAP2LNPEPERAP1CA1CA2 | |
| SCHEMBL6433206 | 0.89 | KLKB1 (0.48) | ERAP2LNPEPERAP1CA1CA2 | |
| SCHEMBL7243074 | 0.88 | HDAC4 (0.48) | ERAP2LNPEPERAP1CA1CA2 | |
| SCHEMBL5970341 | 0.79 | KLKB1 (0.46) | ERAP2LNPEPERAP1 | |
| SCHEMBL5970345 | 0.79 | KLKB1 (0.46) | ERAP2LNPEPERAP1 | |
| SCHEMBL8798419 | 0.71 | NPC1 (0.46) | — | |
| SCHEMBL6350473 | 0.70 | HDAC4 (0.54) | CA1CA2SIRT1 | |
| SCHEMBL5970177 | 0.70 | PLG (0.48) | ERAP2LNPEPCPA1CPA2CPA4 | |
| SCHEMBL6287948 | 0.69 | CA1 (0.49) | CA1CA2SIRT6SIRT1CPA1 | |
| SCHEMBL5970151 | 0.69 | CPA1 (0.46) | CA1CA2SIRT6SIRT1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110959-A1 | Antiangiogenic drug to treat cancer, arthritis and retinopathy | ABBVIE INC. | 2004-06-10 | — | — | US | claimed |
| US-6632961-B1 | Pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to | ABBOTT LABORATORIES | 2003-10-14 | — | — | US | claimed |
| EP-1080070-A2 | ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY | ABBOTT LABORATORIES (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999061406-A2 | ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
| EP-1080070-B1 | ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY | ABBOTT LAB (US) | 2006-11-22 | — | — | EP | disclosed |
| US-6849757-B2 | Antiangiogenic drug to treat cancer, arthritis and retinopathy | ABBOTT LABORATORIES (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040110959-A1 | Antiangiogenic drug to treat cancer, arthritis and retinopathy | ABBVIE INC. | 2004-06-10 | — | — | US | disclosed |
| US-6632961-B1 | Pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to | ABBOTT LABORATORIES | 2003-10-14 | — | — | US | disclosed |
| EP-1080070-A2 | ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY | ABBOTT LABORATORIES (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061406-A2 | ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110959-A1 | Antiangiogenic drug to treat cancer, arthritis and retinopathy | FLT1, VEGFA, KDR | ERAP2 2276/4885LNPEP 3218/4885ERAP1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.